US2019135759A1PendingUtilityA1
Method of treating pain
Est. expiryDec 16, 2031(~5.4 yrs left)· nominal 20-yr term from priority
C07D 215/38A61K 45/06A61K 31/00A61K 31/4709A61P 29/02
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.
Claims
exact text as granted — not AI-modified1 . A compound selected from
a)
wherein R is selected from
wherein R′ is selected from H, CH 3 , Et, or X, and
wherein R″ is selected from H or alkyl;
for use in a method for treating the human or animal body.
2 . The compound of claim 1 , wherein R is
wherein R′ is selected from H, CH 3 , Et, or X, and
wherein R″ is selected from H or alkyl.
3 . The compound of claim 1 or 2 , wherein R is
R′ is H, and R″ is CH 3 .
4 . The compound of any of claims 1 to 3 for use in treating, reducing, or preventing pain in a mammal.
5 . The compound of claim 4 , wherein the pain is selected from acute, chronic, neuropathic, nociceptive and visceral pain, and a combination thereof.
6 . The compound of claim 5 , wherein the pain comprises visceral pain.
7 . The compound of claim 5 , wherein the pain comprises neuropathic pain.
8 . The compound of any of claims 4 to 7 , wherein said compound is administered orally.
9 . The compound of any of claims 4 to 7 , wherein said compound is administered topically.
10 . A pharmaceutical composition comprising the compound of any of claims 1 to 7 and a pharmaceutical excipient.
11 . The pharmaceutical composition of claim 8 , further comprising one or more additional pharmaceutically active agents.
12 . The pharmaceutical composition of claim 9 , wherein said one or more additional pharmaceutically active agents are selected from non-opioid analgesics, opioid analgesics, anti-epileptics, NMDA antagonists, lidocaine, tricyclic antidepressants, or a combination thereof.
13 . A method of treating, reducing, or preventing pain in a mammal, comprising the step of administering a therapeutically effective amount of a composition to said mammal, wherein said composition comprises a compound selected from
a)
wherein R is selected from
wherein R′ is selected from H, CH 3 , Et, or X, and
wherein R″ is selected from H or alkyl;
b)
wherein R is selected from Aryl, heteroaryl, alkyl, cycloalkyl, H, and R′ is selected from H, aryl, heteroaryl, alkyl, cycloalkyl to a subject in need thereof, and wherein said compound is capable of modulating Trpc4 activity.
14 . The method of claim 13 , wherein said compound comprises
wherein R is
wherein R′ is selected from H, CH 3 , Et, or X, and
wherein R″ is selected from H or alkyl.
15 . The method of claim 13 or 14 , wherein said compound comprises
wherein R is
R′ is H, and R″ is CH 3 .
16 . The method of any of claims 13 to 15 , wherein said Trpc4 is human.
17 . The method of any of claims 13 to 16 , wherein said compound causes an increase in Trpc4 activity.
18 . The method of any of claims 13 to 16 , wherein said compound causes a decrease in Trpc4 activity.
19 . The method of any of claims 13 to 16 , wherein said compound functions as a Trpc4 antagonist.
20 . The method of claims 13 to 16 , wherein said compound functions as a Trpc4 agonist.
21 . The method of claim 14 , wherein said compound functions as a Trpc4 antagonist.
22 . The method of claim 14 , wherein said compound functions as a Trpc4 agonist.
23 . The method of any of claims 13 to 22 , wherein the pain is selected from the group consisting of acute, chronic, neuropathic, nociceptive, visceral, and a combination thereof.
24 . The method of claim 13 , wherein the pain comprises visceral pain.
25 . The method of claim 13 wherein the pain comprises neuropathic pain.
26 . The method of any of claims 13 to 25 , wherein said composition further comprises a second pharmaceutically active agent.
27 . The method of any of claims 13 to 26 , wherein said composition further comprises one or more additional pharmaceutically active agents selected from non-opioid analgesics, opioid analgesics, anti-epileptics, NMDA antagonists, lidocaine, tricyclic antidepressants, or a combination thereof.
28 . The method of any of claims 13 to 27 wherein said compound is administered orally.
29 . The method of any of claims 13 to 27 wherein said compound is administered topically.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.